Moleculin Biotech (MBRX) has provided an announcement.
Moleculin Biotech, Inc. has unveiled promising preclinical data for its new cancer drug, Annamycin, at the American Association for Cancer Research Annual Meeting in San Diego. This development could intrigue investors as the company showcases its potential in advancing cancer treatments, signaling a significant milestone in the drug’s journey towards possible commercialization.
See more data about MBRX stock on TipRanks’ Stock Analysis page.
